02.15.24 -- Gene Editing Versus Gene Therapy: Is There A Difference?

New opportunities are being presented to treat previously incurable diseases. Take a look at several solutions being used to overcome development challenges associated with these novel therapeutics.

The issue of classifying or certifying wipes for use arises with increasing frequency. Learn why it's not possible to definitively categorize or certify wipes for specific cleanroom environments.

Drug manufacturers seek packaging that maintains integrity during processing and freezing, scales up to larger volumes easily, and remains robust throughout the temperature-controlled supply chain.

Explore trends that are transforming the industry, common hurdles, and how a new platform is offering unprecedented process transparency and continuous improvement.

The logistics of decoupling drug substance manufacturing from final drug product formulation is now possible using integrated single-use freeze-thaw assemblies that incorporate reliable components.

With a need for more viral-vector manufacturing platforms, consider this advice for overcoming obstacles experienced during transfection, clarification, and the separation of empty and full capsids.

Uncover how a clinical-stage biotechnology startup received assistance in genetic material handling, relationships with key global regulatory agencies, and expertise in accelerated pathways to approval.

Researchers demonstrate a delivery mechanism that is a simple and ready-to-use transfection reagent that leads to outstanding transfection efficiencies in known hard-to-transfect stem cells.

One of the biggest risks for medical products and companies is the failure to report adverse events. But what leads to underreporting? Here are five core reasons behind most adverse event underreporting.